Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients.

Trial Profile

Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Imiquimod (Primary) ; Methyl aminolevulinate
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms AKtransplant
  • Most Recent Events

    • 06 Sep 2012 Planned end date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 07 Jul 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2010-024623-24).
    • 05 Jul 2012 Galderma and Meda added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top